Krystal Biotech, Inc. KRYS Allowance for Doubtful Accounts Receivable (Current)
Allowance for Doubtful Accounts Receivable (Current) at other companies
Other financials
Where this comes from
Reported directly by Krystal Biotech, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AllowanceForDoubtfulAccountsReceivable.
The official record: Krystal Biotech, Inc.’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Krystal Biotech, Inc.'s allowance for doubtful accounts receivable (current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Krystal Biotech, Inc.'s allowance for doubtful accounts receivable (current)?
- Krystal Biotech, Inc. (KRYS) reported allowance for doubtful accounts receivable (current) of $81.34M in Q1 2026.
- How has Krystal Biotech, Inc.'s allowance for doubtful accounts receivable (current) changed year-over-year?
- Krystal Biotech, Inc.'s allowance for doubtful accounts receivable (current) increased by 55.6% year-over-year, from $52.28M to $81.34M.
- What is the long-term trend for Krystal Biotech, Inc.'s allowance for doubtful accounts receivable (current)?
- Over 2 years (2023 to 2025), Krystal Biotech, Inc.'s allowance for doubtful accounts receivable (current) has grown at a 209.4% compound annual growth rate (CAGR), from $7.11M to $68.12M.